Racura raised $34.3m to Advance Three Oncology Trials
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Racura Oncology Ltd has announced the successful raising of funds to support three oncology clinical trials. The total amount raised is significant and will be used for trials in Acute Myeloid Leukaemia, EGFRm lung cancer, and cardioprotection in solid tumour patients. The company expressed gratitude to its shareholders for their continued support during this fundraising initiative. CEO Dr. Daniel Tillett highlighted the confidence shown by shareholders in Racura's mission and future clinical progress.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Racura Oncology
- Emerging Companies Specialist Invests in Racura
- Racura Enters Underwriting Agreement for Options
- Racura Oncology Announces Positive Safety Review Committee Recommendation in ongoing CPACS Clinical Trial
- CPACS Trial Cleared to Escalate to Next RC220 Dose Level
- (E,E)-bisantrene Discovered to Function via Silencing of c-MYC Expression
Later from Racura Oncology
- Racura Treats First Patient in HARNESS-1 Lung Cancer Trial
- Racura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 in EGFR-Mutant Non-Small Cell Lung Cancer
- Bellberry Ethics Approval Activates New HARNESS Trial Sites
- June 2026 Quarterly Activities Report and Appendix 4C
- Racure Oncology Techknow Invest Presentation
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology